BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Previous close
$0.9639
−$0.0965 · -9.10%
Regular session · ET · Market data may be delayed.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Day range
Current $0.9639
52-week range
Current $0.9639
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
52
Mixed
Risk
62
High Risk
Momentum
40
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Day range
Current $0.9639
52-week range
Current $0.9639
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.19M USD | 28.94M USD | 4.8M USD | — | — |
| Cost of goods sold | 758.97K USD | 9.26M USD | 3.69M USD | — | — |
| Gross profit | 430.39K USD | 19.68M USD | 1.11M USD | — | — |
| Research and development | 7.66M USD | 9.15M USD | 12.52M USD | 17.63M USD | 19.47M USD |
| Selling, general, and administrative | 3.14M USD | 28.54M USD | 31.23M USD | 11.53M USD | 5.27M USD |
| Operating expenses | 10.8M USD | 40.09M USD | 50.8M USD | 29.16M USD | 24.78M USD |
| Interest income | 1.13M USD | 1.83M USD | 2.01M USD | 694K USD | 559K USD |
| Interest expense | 1.29M USD | 9.16M USD | 2.17M USD | 2.16M USD | 984K USD |
| Depreciation and amortization | 527.15K USD | 4.07M USD | 1.38M USD | 654K USD | 703K USD |
| Operating income | −10.37M USD | −20.41M USD | −49.69M USD | −29.16M USD | −24.78M USD |
| Net income | −1.18M USD | −9.22M USD | −60.61M USD | −24.95M USD | −27.05M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 30, 2025 | 1:40 | — | — |
Stock split | Jul 15, 2019 | 1:15 | — | — |
Effective Jan 30, 2025
1:40
Effective Jul 15, 2019
1:15
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.